No Data
No Data
Yibai Pharmaceutical (600594.SH) plans to pay 0.066 yuan per share in 2023, excluding interest on June 7
Yibai Pharmaceutical (600594.SH) announced that the company plans to distribute a cash dividend of 0.066 per share in 2023...
Yibai Pharmaceutical (600594.SH): The product Eddy Injection was removed from the Guangdong Union's centralized procurement status of proprietary Chinese medicines such as Qingkailing
Gelonghui, May 17丨Yibai Pharmaceutical (600594.SH) announced that recently, the Guangdong Drug Trade Center issued the “Notice on Cancelling the Status of Guizhou Yibai Pharmaceutical Co., Ltd. Product Eddy Injection” to cancel the selection/alternative status of Guizhou Yibai Pharmaceutical Co., Ltd. product Eddy Injection in Guangdong according to the “Guangdong Alliance Qingkailing and Other Proprietary Chinese Medicines Centralized Volume Procurement Document (GDYJYPDL202103)” on “selected/alternative products suspended production, sales, use, import, etc. by the drug administration department”. Alliance concentrates on proprietary Chinese medicines such as Qingkailing
Yibai Pharmaceuticals (600594.SH): 2023 net profit of 103 million yuan reverses year-on-year losses
Gelonghui, April 18 | Yibai Pharmaceutical (600594.SH) released its 2023 annual report. Operating revenue was 2.82 billion yuan, up 3.12% year on year, net profit of 103 million yuan, reversed year on year loss, after deducting non-net profit of 67.45 million yuan, reversing year on year loss, with basic earnings of 0.131 yuan per share. The company plans to distribute a cash dividend of 0.66 yuan for every 10 shares to all shareholders in 2023.
Guizhou Yibai Pharmaceutical (SHSE:600594 Shareholders Incur Further Losses as Stock Declines 11% This Week, Taking Five-year Losses to 32%
Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long term Guizhou Yibai Pharmaceutic
Failure to disclose in a timely manner the discontinuation of production of major products affects the decisions of Yibai Pharmaceuticals (600594.SH) and related personnel to accept administrative supervision measures
Yibai Pharmaceutical (600594.SH) issued an announcement. The company received an announcement from the China Securities Regulatory Commission and the Guizhou Regulatory Bureau...
The Market Doesn't Like What It Sees From Guizhou Yibai Pharmaceutical Co., Ltd.'s (SHSE:600594) Revenues Yet As Shares Tumble 25%
Guizhou Yibai Pharmaceutical Co., Ltd. (SHSE:600594) shareholders that were waiting for something to happen have been dealt a blow with a 25% share price drop in the last month. Instead of being re
No Data